Does the media prefer RCUS or AXSM?

In the previous week, Axsome Therapeutics had 10 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Axsome Therapeutics and 3 mentions for Arcus Biosciences. Axsome Therapeutics' average media sentiment score of 0.32 beat Arcus Biosciences' score of 0.09 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELAN or RCUS?

In the previous week, Elanco Animal Health had 11 more articles in the media than Arcus Biosciences. MarketBeat recorded 14 mentions for Elanco Animal Health and 3 mentions for Arcus Biosciences. Elanco Animal Health's average media sentiment score of 1.08 beat Arcus Biosciences' score of 0.09 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend RCUS or RGC?

Arcus Biosciences currently has a consensus price target of $33.89, suggesting a potential upside of 41.90%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, RCUS or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Arcus Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcus Biosciences $247M 12.16 -$353M -$3.18 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media favor RCUS or RGC?

In the previous week, Regencell Bioscience had 16 more articles in the media than Arcus Biosciences. MarketBeat recorded 19 mentions for Regencell Bioscience and 3 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.09 beat Regencell Bioscience's score of 0.08 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RDY or RCUS?

In the previous week, Dr. Reddy's Laboratories had 6 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 3 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.09 beat Dr. Reddy's Laboratories' score of -0.65 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ARWR or RCUS?

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 3 mentions for Arcus Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 1.19 beat Arcus Biosciences' score of 0.09 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Arcus Biosciences (RCUS) Competitors

$23.88 -0.59 (-2.40%)

Closing price 03:58 PM Eastern

Extended Trading

$23.87 -0.01 (-0.04%)

As of 04:11 PM Eastern

Compare

RCUS vs. AXSM, ELAN, RGC, RDY, and ARWR

Should you buy Arcus Biosciences stock or one of its competitors? MarketBeat compares Arcus Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcus Biosciences include Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Dr. Reddy's Laboratories (RDY), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Arcus Biosciences compare to Axsome Therapeutics?

Arcus Biosciences (NYSE:RCUS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Arcus Biosciences presently has a consensus target price of $33.89, suggesting a potential upside of 41.90%. Axsome Therapeutics has a consensus target price of $251.26, suggesting a potential upside of 7.69%. Given Arcus Biosciences' higher possible upside, equities analysts plainly believe Arcus Biosciences is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Axsome Therapeutics has higher revenue and earnings than Arcus Biosciences. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A
Axsome Therapeutics	$638.50M	18.80	-$183.17M	-$3.73	N/A

Axsome Therapeutics has a net margin of -26.59% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

In the previous week, Axsome Therapeutics had 10 more articles in the media than Arcus Biosciences. MarketBeat recorded 13 mentions for Axsome Therapeutics and 3 mentions for Arcus Biosciences. Axsome Therapeutics' average media sentiment score of 0.32 beat Arcus Biosciences' score of 0.09 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcus Biosciences has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

Axsome Therapeutics beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Elanco Animal Health has higher revenue and earnings than Arcus Biosciences. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.60	-$232M	-$0.50	N/A
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A

In the previous week, Elanco Animal Health had 11 more articles in the media than Arcus Biosciences. MarketBeat recorded 14 mentions for Elanco Animal Health and 3 mentions for Arcus Biosciences. Elanco Animal Health's average media sentiment score of 1.08 beat Arcus Biosciences' score of 0.09 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Elanco Animal Health has a net margin of -4.95% compared to Arcus Biosciences' net margin of -156.36%. Elanco Animal Health's return on equity of 7.42% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Elanco Animal Health has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Elanco Animal Health presently has a consensus target price of $28.20, suggesting a potential upside of 14.78%. Arcus Biosciences has a consensus target price of $33.89, suggesting a potential upside of 41.90%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Elanco Animal Health beats Arcus Biosciences on 13 of the 17 factors compared between the two stocks.

How does Arcus Biosciences compare to Regencell Bioscience?

Arcus Biosciences (NYSE:RCUS) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Arcus Biosciences has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

In the previous week, Regencell Bioscience had 16 more articles in the media than Arcus Biosciences. MarketBeat recorded 19 mentions for Regencell Bioscience and 3 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.09 beat Regencell Bioscience's score of 0.08 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regencell Bioscience has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Regencell Bioscience's return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Regencell Bioscience	N/A	N/A	N/A

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Arcus Biosciences currently has a consensus price target of $33.89, suggesting a potential upside of 41.90%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Regencell Bioscience has lower revenue, but higher earnings than Arcus Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Summary

Arcus Biosciences beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks.

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Dr. Reddy's Laboratories has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.04	$484.20M	$0.58	22.51
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A

In the previous week, Dr. Reddy's Laboratories had 6 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 3 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.09 beat Dr. Reddy's Laboratories' score of -0.65 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Arcus Biosciences' net margin of -156.36%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories currently has a consensus price target of $16.90, suggesting a potential upside of 29.45%. Arcus Biosciences has a consensus price target of $33.89, suggesting a potential upside of 41.90%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories and Arcus Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Arcus Biosciences (NYSE:RCUS) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.32	-$1.63M	-$2.15	N/A
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Arcus Biosciences. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 3 mentions for Arcus Biosciences. Arrowhead Pharmaceuticals' average media sentiment score of 1.19 beat Arcus Biosciences' score of 0.09 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals currently has a consensus target price of $87.80, suggesting a potential upside of 21.02%. Arcus Biosciences has a consensus target price of $33.89, suggesting a potential upside of 41.90%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Arcus Biosciences' net margin of -156.36%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summary

Arrowhead Pharmaceuticals beats Arcus Biosciences on 13 of the 17 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCUS vs. The Competition

Export

Metric	Arcus Biosciences	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$3.08B	$3.24B	$6.47B	$23.28B
Dividend Yield	N/A	2.38%	2.69%	4.06%
P/E Ratio	-7.51	17.78	22.39	31.00
Price / Sales	12.16	315.63	520.79	23.82
Price / Cash	N/A	111.64	41.34	24.93
Price / Book	4.09	6.63	9.84	4.67
Net Income	-$353M	$24.20M	$3.57B	$1.07B
7 Day Performance	-0.80%	-3.24%	-1.16%	-0.67%
1 Month Performance	-7.16%	0.53%	3.85%	0.22%
1 Year Performance	138.12%	47.24%	27.40%	25.44%

Arcus Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCUS Arcus Biosciences	2.4512 of 5 stars	$23.88 -2.4%	$33.89 +41.9%	+165.3%	$3.08B	$247M	N/A	500
AXSM Axsome Therapeutics	2.3315 of 5 stars	$230.25 -1.8%	$251.26 +9.1%	+106.4%	$12.07B	$708.24M	N/A	380	Insider Trade
ELAN Elanco Animal Health	3.8669 of 5 stars	$23.70 -0.6%	$28.20 +19.0%	+76.0%	$11.91B	$4.89B	N/A	9,400	News Coverage Positive News
RGC Regencell Bioscience	0.1349 of 5 stars	$24.17 +1.1%	N/A	N/A	$11.82B	N/A	N/A	10	Trending News
RDY Dr. Reddy's Laboratories	3.1088 of 5 stars	$13.27 -2.7%	$16.90 +27.4%	-11.6%	$11.38B	$3.58B	22.87	27,811	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RCUS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcus Biosciences (RCUS) Competitors

RCUS vs. AXSM, ELAN, RGC, RDY, and ARWR

How does Arcus Biosciences compare to Axsome Therapeutics?

Summary

How does Arcus Biosciences compare to Elanco Animal Health?

Summary

How does Arcus Biosciences compare to Regencell Bioscience?

Summary

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcus Biosciences (RCUS) Competitors

RCUS vs. AXSM, ELAN, RGC, RDY, and ARWR

How does Arcus Biosciences compare to Axsome Therapeutics?

Do analysts recommend RCUS or AXSM?

Do institutionals & insiders hold more shares of RCUS or AXSM?

Which has better valuation and earnings, RCUS or AXSM?

Is RCUS or AXSM more profitable?

Does the media prefer RCUS or AXSM?

Which has more volatility & risk, RCUS or AXSM?

Summary

How does Arcus Biosciences compare to Elanco Animal Health?

Which has stronger valuation and earnings, ELAN or RCUS?

Does the media prefer ELAN or RCUS?

Is ELAN or RCUS more profitable?

Which has more volatility & risk, ELAN or RCUS?

Do analysts recommend ELAN or RCUS?

Do insiders & institutionals hold more shares of ELAN or RCUS?

Summary

How does Arcus Biosciences compare to Regencell Bioscience?

Which has more volatility & risk, RCUS or RGC?

Does the media favor RCUS or RGC?

Is RCUS or RGC more profitable?

Do institutionals & insiders hold more shares of RCUS or RGC?

Do analysts recommend RCUS or RGC?

Which has preferable earnings & valuation, RCUS or RGC?

Summary

How does Arcus Biosciences compare to Dr. Reddy's Laboratories?

Which has preferable valuation & earnings, RDY or RCUS?

Does the media prefer RDY or RCUS?

Is RDY or RCUS more profitable?

Do institutionals and insiders hold more shares of RDY or RCUS?

Do analysts recommend RDY or RCUS?

Which has more volatility and risk, RDY or RCUS?

Summary

How does Arcus Biosciences compare to Arrowhead Pharmaceuticals?

Which has more volatility & risk, ARWR or RCUS?

Which has higher valuation and earnings, ARWR or RCUS?

Do insiders & institutionals hold more shares of ARWR or RCUS?

Does the media prefer ARWR or RCUS?

Do analysts prefer ARWR or RCUS?

Is ARWR or RCUS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS vs. The Competition

Arcus Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools